MedTrace Logo

Detection of Minimal Residual Disease Post-prostatectomy

NCT07334275 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-01-12

No results posted yet for this study

Summary

The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.

Conditions

Sponsors & Collaborators

  • Catharina Ziekenhuis Eindhoven

    collaborator OTHER

  • Canisius-Wilhelmina Hospital

    collaborator OTHER

  • Maxima Medical Center

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-16
Primary Completion
2027-07-31
Completion
2028-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07334275 on ClinicalTrials.gov